Lab Site Clinical LLC

Lab Site Clinical LLC was paid $202K by Medicaid between May 2020 and Apr 2024, across 25 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 55% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Louisiana

Rank by total paid#36 of 66

Median peer was paid$253K

This provider vs. median0.8×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2020	1,198	$5K
2021	4,284	$90K
2022	3,964	$86K
2023	1,659	$19K
2024incomplete	33	$1K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	55%	1,942	1,628	$112K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	17%	2,090	1,631	$35K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	10%	2,211	1,692	$20K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	8.2%	653	405	$17K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	4.5%	683	301	$9K
87426	Infectious agent antigen detection, SARS-CoV-2 (COVID-19)	1.4%	110	98	$3K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	1,248	872	$1K
80061	Lipid panel	<1%	515	417	$1K
80053	Comprehensive metabolic panel	<1%	892	686	$1K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	47	40	$763.78
83036	Hemoglobin; glycosylated (A1C)	<1%	317	227	$629.14
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	55	48	$395.78

13 more codes

0012A		<1%	14	$241.77
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	12	$235.68
86803		<1%	35	$144.62
84443	Thyroid stimulating hormone (TSH)	<1%	114	$122.21
86709		<1%	37	$121.93
86706		<1%	15	$48.01
86592		<1%	30	$45.67
87340		<1%	16	$44.00
84481		<1%	16	$36.26
84439		<1%	17	$23.06
80164		<1%	14	$13.48
82947		<1%	16	$8.54
91301		0%	39	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialPROVOST, GAIL (CEO)